Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wyndham Hotels & Resorts (WH) initiated with a Buy at Jefferies and an Overweight at JPMorgan. 2. Nxt-ID (NXTD) initiated with a Buy at Euro Pacific. 3. Infinity Pharmaceuticals (INFI) initiated with a Buy at Seaport Global. 4. Edwards Lifesciences (EW) and Medtronic (MDT) were initiated with an Outperform at Raymond James. 5. Rollins (ROL) initiated with a Hold at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

Sees Q2 revenue $1.62B-$1.7B, consensus $1.64B.

Reports Q1 revenue $1.6B, consensus $1.57B. "Edwards is positioned to extend our leadership and deliver sustainable growth as a result of the strategic investments we have made across our transcatheter platforms to address the large and growing needs of patients impacted by aortic, mitral and tricuspid disease. We are pleased with our total company performance with first quarter sales growth of 10% as more patients were treated with our innovative therapies," said Bernard Zovighian, CEO. "This encouraging start to the year supports our increased 2024 sales guidance. Looking beyond 2024, we remain confident in Edwards' innovation-driven strategy, led by new indications, differentiated technologies and strategic adjacencies for addressing the significant unmet needs of structural heart disease patients."

Pre-earnings options volume in Edwards Lifesciences is 5.5x normal with puts leading calls 10:7. Implied volatility suggests the market is anticipating a move near 4.8%, or $4.27, after results are released. Median move over the past eight quarters is 6.3%.

Reports Q1 revenue $304M, consensus $308.26M. Global RevPAR grew 1% in constant currency and ancillary revenues grew 8% compared to Q1 2023. "We're thrilled to announce another strong quarter of progress in our executions, openings, franchisee retention and net room growth around the world," said CEO Geoff Ballotti. "Increased interest from hotel owners in our brands has propelled our development pipeline to a record 243,000 rooms, marking an impressive 8% increase. Our strong balance sheet and cash flow generation capabilities provide significant opportunity to continue to enhance returns to our shareholders over both the short and long-term, as evidenced by our Board of Directors' approval of a $400M increase in our share repurchase authorization."